{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:05Z","timestamp":1753891865696,"version":"3.41.2"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Esophageal cancer is among the leading causes of cancer-related mortality in males. This study aimed to evaluate the efficacy and safety of nedaplatin (NDP) in comparison to other platinum-based (OPB) agents combined with paclitaxel and concurrent neoadjuvant radiotherapy for locally advanced thoracic segmental esophageal squamous cell carcinoma (ESCC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single-center, retrospective cohort study was conducted in China. The primary endpoints of this study were safety and efficacy assessments. Unpaired t-tests, chi-squared tests, and Fisher\u2019s exact tests were used to compare intergroup differences, as appropriate. Multivariate logistic regression models were used to explore the associations between postoperative outcomes and the two treatment groups. Kaplan\u2013Meier survival curves and Cox proportional hazards regression models based on OS and PFS were used to compare the efficacy between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 212 patients were enrolled in this retrospective cohort study, including 79 who received NDP and 133 who received OPB (82 were treated with cisplatin, 20 with carboplatin, 19 with lobaplatin, and 12 with oxaliplatin) agents. The incidences of grade 3\u20134 acute radiotherapy-associated esophagitis, pneumonitis, and leukemia were significantly lower in the NDP group than in the OPB group (p = 0.02, p &amp;lt; 0.001, and p = 0.002, respectively). All grades of acute gastrointestinal reactions, including nausea, vomiting, anorexia, and diarrhea, were significantly more frequent in the OPB group than in the NPD group (p &amp;lt; 0.001, p = 0.032, p &amp;lt; 0.001, and p = 0.002, respectively). The Kaplan\u2013Meier curves for overall survival (OS) and progression-free survival (PFS) showed similar results for both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The safety profile of nedaplatin may be superior to those of other platinum-based agents in terms of acute radiotherapy toxicity and postoperative side effects; however, there was no difference in the efficacy between the two groups regarding short-term prognostic tumor regression grades or long-term OS and PFS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1582481","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:10:35Z","timestamp":1747109435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Qingyang","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiancheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinluan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J clinicians"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849984","article-title":"Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an open-label, single-arm study (PEN-ICE)","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104515","article-title":"Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial","volume":"90","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1031171","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000978","article-title":"Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0874-8","article-title":"Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma","volume":"64","author":"Gong","year":"2009","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/jp9056835","article-title":"The second-generation anticancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism","volume":"113","author":"Alberto","year":"2009","journal-title":"J Phys Chem B"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1021\/ic200148n","article-title":"Which one among the Pt-containing anticancer drugs more easily forms monoadducts with G and A DNA bases? A comparative study among oxaliplatin, nedaplatin, and carboplatin","volume":"50","author":"Alberto","year":"2011","journal-title":"Inorganic Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/pharmaceutics14020418","article-title":"Enhanced anticancer activity of nedaplatin loaded onto copper nanoparticles synthesized using red algae","volume":"14","author":"Aboeita","year":"2022","journal-title":"Pharmaceutics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601700","article-title":"Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma","volume":"90","author":"Sekine","year":"2004","journal-title":"Br J cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00305-8","article-title":"Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial","volume":"16","author":"Shukuya","year":"2015","journal-title":"Lancet Oncology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp058","article-title":"A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer","volume":"39","author":"Cao","year":"2009","journal-title":"Japanese J Clin oncology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.006","article-title":"Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - A multicenter, open-label, randomized, phase III trial","volume":"13","author":"Lu","year":"2018","journal-title":"J thoracic oncology: Off Publ Int Assoc Study Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.002","article-title":"Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors","volume":"115","author":"Mabuchi","year":"2009","journal-title":"Gynecologic oncology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30104-9","article-title":"Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial","volume":"19","author":"Tang","year":"2018","journal-title":"Lancet Oncology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.38470","article-title":"Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: A 5-year follow-up secondary analysis of a randomized clinical trial","volume":"4","author":"Tang","year":"2021","journal-title":"JAMA network Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.05.041","article-title":"A phase 1\/2 study of definitive chemoradiation therapy using docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for esophageal cancer","volume":"93","author":"Ohnuma","year":"2015","journal-title":"Int J Radiat oncology biology physics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.08.069","article-title":"Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study","volume":"78","author":"Zhang","year":"2010","journal-title":"Int J Radiat oncology biology physics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23487","article-title":"Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity","volume":"36","author":"Xu","year":"2014","journal-title":"Head neck"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000000170","article-title":"A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer","volume":"26","author":"Du","year":"2015","journal-title":"Anti-cancer Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2076-2","article-title":"Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer","volume":"71","author":"Miyazaki","year":"2013","journal-title":"Cancer chemotherapy Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq196","article-title":"Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer","volume":"41","author":"Ohashi","year":"2011","journal-title":"Japanese J Clin oncology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpca.8b04023","article-title":"Raman and infrared studies of platinum-based drugs: cisplatin, carboplatin, oxaliplatin, nedaplatin, and heptaplatin","volume":"122","author":"Torres","year":"2018","journal-title":"J Phys Chem A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i35.5910","article-title":"A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma","volume":"19","author":"He","year":"2013","journal-title":"World J gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01021-1","article-title":"Recombinant human endostatin plus paclitaxel\/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study","volume":"39","author":"Wang","year":"2021","journal-title":"Investigational New Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1293\/tox.24.87","article-title":"Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics","volume":"24","author":"Uehara","year":"2011","journal-title":"J toxicologic pathology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2012.09.001","article-title":"Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase","volume":"265","author":"Wang","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.1385","article-title":"Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation","volume":"28","author":"Kawai","year":"2005","journal-title":"Biol pharmaceutical bulletin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181add9c7","article-title":"Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic\/recurrent esophageal squamous cell carcinoma","volume":"4","author":"Jin","year":"2009","journal-title":"J thoracic oncology: Off Publ Int Assoc Study Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/pharmaceutics12090863","article-title":"Encapsulation of nedaplatin in novel PEGylated liposomes increases its cytotoxicity and genotoxicity against A549 and U2OS human cancer cells","volume":"12","author":"El-Shafie","year":"2020","journal-title":"Pharmaceutics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2017.12.070","article-title":"Investigation of the host-guest complexation between 4-sulfocalix[4]arene and nedaplatin for potential use in drug delivery","volume":"193","author":"Fahmy","year":"2018","journal-title":"Spectrochimica Acta Part A Mol biomolecular spectroscopy"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124994","article-title":"Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53\/Bcl-2 Pathway in Hepatocellular Carcinoma Cells","volume":"10","author":"Jiang","year":"2015","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0587-9","article-title":"Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer","volume":"11","author":"Yamashita","year":"2016","journal-title":"Radiat Oncol (London England)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13772","article-title":"Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study","volume":"109","author":"Ohnuma","year":"2018","journal-title":"Cancer science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.10.20","article-title":"Three-field lymph node dissection in treating the esophageal cancer","volume":"8","author":"Shang","year":"2016","journal-title":"J thoracic disease"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S168391","article-title":"Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating Malignant pleural effusion","volume":"11","author":"Zhong","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12490","article-title":"Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic\/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"30","author":"Zhang","year":"2017","journal-title":"Dis esophagus: Off J Int Soc Dis Esophagus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1634\/theoncologist.2018-0653","article-title":"Phase II trial of 5-fluorouracil, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer","volume":"24","author":"Ueda","year":"2019","journal-title":"oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-542","article-title":"Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study","volume":"12","author":"Jingu","year":"2012","journal-title":"BMC cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.11.004","article-title":"Involved-field irradiation concurrently combined with nedaplatin\/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study","volume":"113","author":"Yamashita","year":"2014","journal-title":"Radiotherapy oncology: J Eur Soc Ther Radiol Oncology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq781","article-title":"Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung","volume":"22","author":"Naito","year":"2011","journal-title":"Ann oncology: Off J Eur Soc Med Oncology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02804-y","article-title":"Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC","volume":"21","author":"Li","year":"2023","journal-title":"BMC medicine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4440-4","article-title":"Phase II study of docetaxel, nedaplatin, and 5-fluorouracil combined chemotherapy for advanced esophageal cancer","volume":"22","author":"Miyazaki","year":"2015","journal-title":"Ann Surg oncology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.05.021","article-title":"Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer","volume":"85","author":"Isohashi","year":"2013","journal-title":"Int J Radiat oncology biology physics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13014-015-0486-5","article-title":"Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters","volume":"10","author":"Isohashi","year":"2015","journal-title":"Radiat Oncol (London England)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02057-w","article-title":"Establishment of nedaplatin safety dose formula based on renal function for combination chemotherapy with nedaplatin and 5-fluorouracil in patients with esophageal cancer","volume":"27","author":"Takahashi","year":"2022","journal-title":"Int J Clin oncology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605875","article-title":"Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer","volume":"103","author":"Oshita","year":"2010","journal-title":"Br J cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.radonc.2017.04.002","article-title":"Involved-field irradiation concurrently combined with nedaplatin\/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study","volume":"123","author":"Yamashita","year":"2017","journal-title":"Radiotherapy oncology: J Eur Soc Ther Radiol Oncology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2019.134974","article-title":"Ecological processes underlying community assembly of aquatic bacteria and macroinvertebrates under contrasting climates on the Tibetan Plateau","volume":"702","author":"Vilmi","year":"2020","journal-title":"Sci total environment"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1582481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:10:36Z","timestamp":1747109436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1582481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":51,"alternative-id":["10.3389\/fonc.2025.1582481"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1582481","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"article-number":"1582481"}}